Silvia Romano

List of Publications by Year
in descending order

107 papers	3,700 citations	159358 30 h-index	138251 58 g-index
118 all docs	118 docs citations	118 times ranked	5600 citing authors

#	Article	IF	Citations
1	Cognitive Reserve in Early Manifest Huntington Disease Patients: Leisure Time Is Associated with Lower Cognitive and Functional Impairment. Journal of Personalized Medicine, 2022, 12, 36.	1.1	7
2	Clinical-Genetic Features Influencing Disability in Spastic Paraplegia Type 4. Neurology: Genetics, 2022, 8, e664.	0.9	9
3	Multiple sclerosis genetic and non-genetic factors interact through the transient transcriptome. Scientific Reports, 2022, 12, 7536.	1.6	4
4	Heterozygous KIF1A variants underlie a wide spectrum of neurodevelopmental and neurodegenerative disorders. Journal of Medical Genetics, 2021, 58, 475-483.	1.5	21
5	Detection of disability worsening in relapsingâ€remitting multiple sclerosis patients: a realâ€world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register. European Journal of Neurology, 2021, 28, 567-578.	1.7	6
6	Machine Learning Use for Prognostic Purposes in Multiple Sclerosis. Life, 2021, 11, 122.	1.1	21
7	A Case of Double Standard: Sex Differences in Multiple Sclerosis Risk Factors. International Journal of Molecular Sciences, 2021, 22, 3696.	1.8	12
8	Circulating hsa-miR-323b-3p in Huntington's Disease: A Pilot Study. Frontiers in Neurology, 2021, 12, 657973.	1.1	11
9	MAIT Cells and Microbiota in Multiple Sclerosis and Other Autoimmune Diseases. Microorganisms, 2021, 9, 1132.	1.6	14
10	The neurobiological underpinning of the social cognition impairments in patients with spinocerebellar ataxia type 2. Cortex, 2021, 138, 101-112.	1.1	22
11	Cognitive and behavioral associated changes in manifest Huntington disease: A retrospective crossâ€sectional study. Brain and Behavior, 2021, 11, e02151.	1.0	12
12	Intestinal Permeability and Circulating CD161+CCR6+CD8+T Cells in Patients With Relapsingâ€“Remitting Multiple Sclerosis Treated With Dimethylfumarate. Frontiers in Neurology, 2021, 12, 683398.	1.1	5
13	F19â€…Cognitive reserve: the leisure time concurs to the cognition performance and to the independence of early huntington disease patients. , 2021, , .		0
14	GWAS-associated variants, non-genetic factors, and transient transcriptome in multiple sclerosis etiopathogenesis: A colocalization analysis. Journal of the Neurological Sciences, 2021, 429, 118157.	0.3	0
15	Clinical and genetic features of a large cohort of Italian SPG4 patients from the D.A.I.S.Y. collaborative network. Journal of the Neurological Sciences, 2021, 429, 118251.	0.3	0
16	Exit strategies for â€œneedle fatigueâ€•in multiple sclerosis: a propensity score-matched comparison study. Journal of Neurology, 2020, 267, 694-702.	1.8	6
17	Considering patient clinical history impacts performance of machine learning models in predicting course of multiple sclerosis. PLoS ONE, 2020, 15, e0230219.	1.1	30
18	Disentangling the molecular mechanisms of multiple sclerosis: The contribution of twin studies. Neuroscience and Biobehavioral Reviews, 2020, 111, 194-198.	2.9	7

#	Article	IF	Citations
19	Frataxin deficiency in Friedreichâ€™s ataxia is associated with reduced levels of HAX-1, a regulator of cardiomyocyte death and survival. Human Molecular Genetics, 2020, 29, 471-482.	1.4	8
20	Reworking GWAS Data to Understand the Role of Nongenetic Factors in MS Etiopathogenesis. Genes, 2020, 11, 97.	1.0	4
21	Functional Changes of Mentalizing Network in SCA2 Patients: Novel Insights into Understanding the Social Cerebellum. Cerebellum, 2020, 19, 235-242.	1.4	17
22	Listening to the neurological teams for multiple sclerosis: the SMART project. Neurological Sciences, 2020, 41, 2231-2240.	0.9	6
23	Title is missing!. , 2020, 15, e0230219.		0
24	Title is missing!. , 2020, 15, e0230219.		0
25	Title is missing!. , 2020, 15, e0230219.		0
26	Title is missing!. , 2020, 15, e0230219.		0
27	DNA damage signatures in peripheral blood cells as biomarkers in prodromal huntington disease. Annals of Neurology, 2019, 85, 296-301.	2.8	28
28	Drug Holiday of Interferon Beta 1b in Multiple Sclerosis: A Pilot, Randomized, Single Blind Study of Non-inferiority. Frontiers in Neurology, 2019, 10, 695.	1.1	5
29	The Contribution of Gut Barrier Changes to Multiple Sclerosis Pathophysiology. Frontiers in Immunology, 2019, 10, 1916.	2.2	39
30	Genome-Wide Multiple Sclerosis Association Data and Coagulation. Frontiers in Neurology, 2019, 10, 95.	1.1	7
31	Novel homozygous GBA2 mutation in a patient with complicated spastic paraplegia. Clinical Neurology and Neurosurgery, 2018, 168, 60-63.	0.6	9
32	Structural cerebellar correlates of cognitive functions in spinocerebellar ataxia type 2. Journal of Neurology, 2018, 265, 597-606.	1.8	44
33	Intestinal Permeability in Relapsing-Remitting Multiple Sclerosis. Neurotherapeutics, 2018, 15, 68-74.	2.1	55
34	Bacille Calmette-GuÃ©rin (BCG) Vaccine in Neuroinflammation. , 2018, , 25-38.		0
35	Bridging the gap between vaccination with Bacille Calmette-GuÃ©rin (BCG) and immunological tolerance: the cases of type 1 diabetes and multiple sclerosis. Current Opinion in Immunology, 2018, 55, 89-96.	2.4	45
36	Analysis of coding and non-coding transcriptome of peripheral B cells reveals an altered interferon response factor (IRF)-1 pathway in multiple sclerosis patients. Journal of Neuroimmunology, 2018, 324, 165-171.	1.1	10

#	Article	IF	Citations
37	The cerebellar topography of attention sub-components in spinocerebellar ataxia type 2. Cortex, 2018, 108, 35-49.	1.1	14
38	Reduced Cancer Incidence in Huntington's Disease: Analysis in the Registry Study. Journal of Huntington's Disease, 2018, 7, 209-222.	0.9	14
39	Leptomeningitis in a Person with Radiologically Isolated Syndrome and Latent Tuberculosis: A Case Report with Implications for Clinical Research. Journal of Medical Imaging and Case Reports, 2018, 02, .	0.1	0
40	D12â€...DNA damage signatures in peripheral lymphocytes as biomarkers in prodromal huntington disease. , 2018, , .		0
41	Altered intestinal permeability in patients with relapsingâ€“remitting multiple sclerosis: A pilot study. Multiple Sclerosis Journal, 2017, 23, 442-446.	1.4	107
42	Chemical Elements and Oxidative Status in Neuroinflammation. , 2017, , 67-81.		0
43	Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study. Lancet Neurology, The, 2017, 16, 701-711.	4.9	248
44	Neural substrates of motor and cognitive dysfunctions in SCA2 patients: A network based statistics analysis. NeuroImage: Clinical, 2017, 14, 719-725.	1.4	36
45	A staged screening of registered drugs highlights remyelinating drug candidates for clinical trials. Scientific Reports, 2017, 7, 45780.	1.6	31
46	Microstructural MRI Basis of the Cognitive Functions in Patients with Spinocerebellar Ataxia Type 2. Neuroscience, 2017, 366, 44-53.	1.1	31
47	Cognitive decline in Huntington's disease expansion gene carriers. Cortex, 2017, 95, 51-62.	1.1	50
48	Coincident onset of multiple sclerosis and Herpes simplex virus 1 encephalitis: a case report. Multiple Sclerosis and Demyelinating Disorders, 2017, 2, .	1.1	11
49	Collaboration between a human group and artificial intelligence can improve prediction of multiple sclerosis course: a proof-of-principle study. F1000Research, 2017, 6, 2172.	0.8	26
50	Collaboration between a human group and artificial intelligence can improve prediction of multiple sclerosis course: a proof-of-principle study. F1000Research, 2017, 6, 2172.	0.8	21
51	Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-309690.	0.9	90
52	Spinocerebellar Ataxia Type 3 in Italy: Time to Change Mind. Neuroepidemiology, 2016, 46, 268-268.	1.1	0
53	Huntington's disease and suicidal behavior: The importance of lithium treatment. Clinical Neurology and Neurosurgery, 2016, 145, 108-109.	0.6	5
54	Clinical manifestations of intermediate allele carriers in Huntington disease. Neurology, 2016, 87, 571-578.	1.5	37

#	Article	IF	Citations
55	D6â€...Dna damage in lymphocytes as a predictor of illness evolution in pre-manifest and overt huntingtonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A35.3-A36.	0.9	0
56	Riluzole in patients with hereditary cerebellar ataxia â€“ Authors' reply. Lancet Neurology, The, 2016, 15, 789.	4.9	5
57	Analyzing the Effects of a G137V Mutation in the FXN Gene. Frontiers in Molecular Neuroscience, 2015, 8, 66.	1.4	14
58	IFN-Î² Therapy Regulates TLR7-Mediated Response in Plasmacytoid Dendritic Cells of Multiple Sclerosis Patients Influencing an Anti-Inflammatory Status. Journal of Interferon and Cytokine Research, 2015, 35, 668-681.	0.5	10
59	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Multiple Sclerosis Journal, 2015, 21, 1013-1024.	1.4	249
60	Epstein-Barr virus genetic variants are associated with multiple sclerosis. Neurology, 2015, 84, 1362-1368.	1.5	44
61	Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2015, 14, 985-991.	4.9	163
62	IFN-Î² and multiple sclerosis: From etiology to therapy and back. Cytokine and Growth Factor Reviews, 2015, 26, 221-228.	3.2	28
63	Effects of the Bacillus Calmette-GuÃ©rin (BCG) Vaccine in the Demyelinating Disease of the Central Nervous System. , 2014, , 63-80.		1
64	Effects of Bacille Calmette-GuÃ©rin after the first demyelinating event in the CNS. Neurology, 2014, 83, 380-381.	1.5	2
65	A shared haplotype for dentatorubropallidoluysian atrophy (DRPLA) in Italian families testifies of the recent introduction of the mutation. Journal of Human Genetics, 2014, 59, 153-157.	1.1	6
66	Domestic accidents and multiple sclerosis: an exploratory study of occurrence and possible causes. Disability and Rehabilitation, 2014, 36, 2205-2209.	0.9	7
67	Effects of Bacille Calmette-GuErin after the first demyelinating event in the CNS. Neurology, 2014, 83, 293-293.	1.5	1
68	Screening for neurotropic viruses in cerebrospinal fluid of patients with multiple sclerosis and other neurological diseases. Multiple Sclerosis Journal, 2014, 20, 638-638.	1.4	2
69	Effects of Sapropterin on Endothelium-Dependent Vasodilation in Patients With CADASIL. Stroke, 2014, 45, 2959-2966.	1.0	16
70	Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. Neurological Sciences, 2014, 35, 307-316.	0.9	30
71	Effects of Bacille Calmette-GuÃ©rin after the first demyelinating event in the CNS. Neurology, 2014, 82, 41-48.	1.5	128
72	B cell IRF1 pathway is dysregulated in multiple sclerosis. Journal of Neuroimmunology, 2014, 275, 1.	1.1	1

#	Article	IF	Citations
73	160. Cytokine, 2014, 70, 67.	1.4	0
74	Cognitive Dysfunctions in Multiple Sclerosis. , 2013, , 133-153.		1
75	Suicidal ideation in a European Huntington's disease population. Journal of Affective Disorders, 2013, 151, 248-258.	2.0	74
76	A â€œCandidate-Interactomeâ€•Aggregate Analysis of Genome-Wide Association Data in Multiple Sclerosis. PLoS ONE, 2013, 8, e63300.	1.1	66
77	The V471A Polymorphism in Autophagy-Related Gene ATG7 Modifies Age at Onset Specifically in Italian Huntington Disease Patients. PLoS ONE, 2013, 8, e68951.	1.1	49
78	Î²-Defensin Genomic Copy Number Does Not Influence the Age of Onset in Huntington's Disease. Journal of Huntington's Disease, 2013, 2, 107-124.	0.9	1
79	Upcoming Meetings Related to Huntington's Disease. Journal of Huntington's Disease, 2013, 2, 135-135.	0.9	0
80	Clinical Presentation. , 2013, , 11-19.		0
81	Assessment Instruments. , 2013, , 37-41.		0
82	Etiopathogenesis. , 2013, , 21-25.		0
83	Impaired vasoreactivity in mildly disabled CADASIL patients. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 268-274.	0.9	18
84	Discrepancies in reporting the CAG repeat lengths for Huntington's disease. European Journal of Human Genetics, 2012, 20, 20-26.	1.4	20
85	CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology, 2012, 78, 690-695.	1.5	303
86	Observing Huntington's disease: the European Huntington's Disease Network's REGISTRY. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1409-1412.	0.9	82
87	CD161highCD8+T cells bear pathogenetic potential in multiple sclerosis. Brain, 2011, 134, 542-554.	3.7	211
88	NMDA receptor gene variations as modifiers in Huntington disease: a replication study. PLOS Currents, 2011, 3, RRN1247.	1.4	20
89	Fractal Analysis Reveals Reduced Complexity of Retinal Vessels in CADASIL. PLoS ONE, 2011, 6, e19150.	1.1	39
90	Aspetti clinici generali. , 2011, , 3-31.		0

#	Article	IF	Citations
91	A Novel Polymorphic APâ€1 Binding Element of the GFAP Promoter is Associated with Different Allelic Transcriptional Activities. Annals of Human Genetics, 2010, 74, 506-515.	0.3	14
92	Multiparametric MR investigation of the motor pyramidal system in patients with â€˜truly benignâ€™ multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 178-188.	1.4	12
93	Riluzole in cerebellar ataxia. Neurology, 2010, 74, 839-845.	1.5	171
94	Identification of novel and recurrent CACNA1A gene mutations in fifteen patients with episodic ataxia type 2. Journal of the Neurological Sciences, 2010, 291, 30-36.	0.3	63
95	Observing Huntingtonâ€™s Disease: the European Huntingtonâ€™s Disease Networkâ€™s REGISTRY. PLOS Currents, 2010, 2, RRN1184.	1.4	124
96	Normal and mutant HTT interact to affect clinical severity and progression in Huntington disease. Neurology, 2009, 73, 1280-1285.	1.5	84
97	Adult-onset Alexander disease: a series of eleven unrelated cases with review of the literature. Brain, 2008, 131, 2321-2331.	3.7	169
98	Can MR Imaging Diagnose Adult-Onset Alexander Disease?. American Journal of Neuroradiology, 2008, 29, 1190-1196.	1.2	99
99	GFAP mutations and polymorphisms in 13 unrelated Italian patients affected by Alexander disease. Clinical Genetics, 2007, 72, 427-433.	1.0	29
100	Brainstem signs with progressing atrophy of medulla oblongata and upper cervical spinal cord. Lancet Neurology, The, 2007, 6, 562-570.	4.9	21
101	Multiple sclerosis: pharmacogenomics and personalised drug treatment. Neurological Sciences, 2006, 27, s347-s349.	0.9	2
102	Propriospinal myoclonus with life threatening tonic spasms as paraneoplastic presentation of breast cancer. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 77, 422-424.	0.9	15
103	Corticosteroids treatment. Journal of the Neurological Sciences, 2004, 223, 47-51.	0.3	43
104	Cerebrospinal fluid isoprostanes are not related to inflammatory activity in relapsingâ€“remitting multiple sclerosis. Journal of the Neurological Sciences, 2004, 224, 23-27.	0.3	24
105	Procerus sign in progressive supranuclear palsy. Neurology, 2001, 57, 1928-1928.	1.5	46
106	Viruses and neuroinflammation in multiple sclerosis. , 0, , .		6
107	DNA Damage Signatures in Peripheral Blood Cells as Biomarkers in Prodromal Huntington's Disease. SSRN Electronic Journal, 0, , .	0.4	0